comparemela.com

Latest Breaking News On - Ikena oncology inc - Page 2 : comparemela.com

Wedbush Downgrades Ikena Oncology (NASDAQ:IKNA) to Neutral

Ikena Oncology (NASDAQ:IKNA – Get Free Report) was downgraded by equities researchers at Wedbush from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. They currently have a $2.00 target price on the stock, down from their previous target price of $8.00. Wedbush’s […]

United statesSg americas securitiesYork mellon corpBarclays plcIkena oncology incIkena oncologyGet free reportMarketbeat ratingsNew york mellon corpCapital managementAdage capital partnersCapital partnersIkena oncology daily

Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday s Mid-Day Session - Bank of Montreal (NYSE:BMO)

United statesSebastiano pettiPaul changNephron sterile compounding centersInnovative eyewear incCue health incSemler scientific incKintara therapeutics incAbercrombie fitch coJp morganImmunovant incGyre therapeutics incOnfolio holdingsCheche group incOnfolio holdings incSiyata mobile inc

Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It Disappointing

Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It Disappointing
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Ikena oncology inc

Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It Disappointing - Ikena Oncology (NASDAQ:IKNA)

Ikena Oncology halts its IK-930 program after reviewing clinical data and resources, focusing on the novel MEK-RAF molecular glue, IK-595.

William blairIkena oncology inc

Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;.

United statesMark manfrediJotin marangoRebecca cohenMike tattoryExchange commissionIkena oncology incChief executive officerSelective hippo pathwayChief financialPrivate securities litigation reform actQuarterly report

vimarsana © 2020. All Rights Reserved.